Advanced epithelial ovarian cancer in the elderly: Chemotherapy tolerance and outcome

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 611-617

  Efstathiou, Eleni ^a   Dimopoulos, Meletios A ^a   Bozas, George ^a   Kastritis, Efstathios ^a   Moulopoulos, Lia A ^a   Rodolakis, Alexandros ^a   Vlahos, George ^a   Gika, Dimitra ^a   Papadimitriou, Christos ^a   Bamias, Aristotelis ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Chemotherapy; Elderly; Ovarian cancer; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TOLERANCE; ELDERLY CARE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847697338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jemal A, Murray T, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Yancik R and Ries LA: Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14: 17-24, 2000.
3. Zagonel V, Monfardini S, Tirelli U, Carbone A and Pinto A: Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy. Crit Rev Oncol Hematol 39: 289-305, 2001.
4. Diaz R, Aparicio J, Molina J, Palomar L, Ponce J, Segura A and Gomez-Codina J: Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol 23: 347-358, 2006.
5. Tirelli U, Zagonel V, Errante D, Fratino L and Monfardini S: Treatment of non-Hodgkin's lymphoma in the elderly: an update. Hematol Oncol 16: 1-13, 1998.
6. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA Jr and Kelly K: Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol 24: 4405-4411, 2006.
7. Bamias A, Efstathiou E, Moulopoulos LA, Gika D, Hamilos G, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C and Dimopoulos MA: The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16: 307-313, 2005.
8. McGuire WP, Hoskins WJ, Brady MF, Krucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
9. Piccart MJ, Bertlensen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three years results. J Natl Cancer Inst 92: 699-708, 2000.
10. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. J Clin Oncol 21: 3194-3200, 2003.
11. DuBois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1330, 2003.
12. Ries LAG: Ovarian cancer. Survival and treatment differences by age. Cancer 71: 524-529, 1993.
13. Thigpen T, Brady MF, Omura G, Creasman WT, McGuire WP, Hoskins WJ and Williams S: Age as prognostic factor in ovarian carcinoma. Cancer 71: 606-614, 1993.
14. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71: 517-523, 1993.
15. Gronlund B, Høgdall C, Hansen HH and Engelholm SA: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94: 1961-1967, 2002.
16. Pignata S and Vermerken JB: Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49: 77-86, 2004.
17. Sundararajan V, Hershman D, Grant VR, Jacobson JS and Neugut AI: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20: 173-178, 2002.
18. Cockroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
19. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
20. Miller AB, Hoogstraten B and Staquet M: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
21. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
22. Cox DR and Oakes D: Analysis of survival data. London, UK, Chapman and Hall, 1984.
23. Berchuck A, Kohler M, Boente MP, Rodriguez GC, Whitaker RS and Bast RC Jr: Growth regulation and transformation of ovarian epithelium. Cancer 71: 545-551, 1993.
24. Pignata S and Monfardini S: Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian cancer. Eur J Cancer 36: 817-820, 2000.
25. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259, 2002.
26. Hightower RD, Nguyen HN, Averette HE, Hoskins W, Harrison T and Steren A: A national survey of ovarian carcinoma IV: patterns of care and related survival for older patients. Cancer 73: 377-383, 1994.
27. Susini T, Scambia G, Magariti PA, Giannice R, Signorile P, Benedetti Panici P and Mancuso S: Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol 75: 437-443, 1994.
28. Sharma S, Driscoll D, Odunsi K, Venkatadri A and Lele S: Safety and efficacy of cytoreductive surgery for epithelial ovarian cacner in elderly and high-risk surgical patients. Am J Obst Gynecol 193: 2077-2082, 2005.
29. Ceccaroni M, D'Agostino G, Ferrandina G, Gadducci A, Di Vagno G, Pignata S, Poerio A, Salerno MG, Fanucchi A, Lapresa MT, Tambaro R and Scambia G: Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 85: 445-450, 2002.
30. Higgins RV, Naumann RW, Gardner J and Hall JB: Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and Carboplatin. Gynecol Oncol 75: 464-467, 1999.
31. ICON collaborators. Paclitaxel plus Carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and Cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 360: 505-515, 2002.
32. Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK and Jolles CJ: Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer 71: 618-627, 1993.
33. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA and Kaye SB: Does aggressive surgery only benefit patients with less than advanced ovarian cancer? Results from am international comparison within the SCOTROC-1 trial. J Clin Oncol 23: 8802-8811, 2005.
34. Warlam-Rodenhuis CC, Koot VC, van der Luijt RB, Vasen HF and Ausems MG: A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients. Eur J Cancer 41: 1409-1415, 2005.
35. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA and Karlan BY: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195, 2003.
36. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR and Venuta S: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88: 1285-1291, 2003.
37. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA, Johnston PG and Harkin DP: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20: 6123-6131, 2001.